WS6
Modify Date: 2024-01-02 13:57:16
WS6 structure
|
Common Name | WS6 | ||
|---|---|---|---|---|
| CAS Number | 1421227-53-3 | Molecular Weight | 568.590 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 744.1±60.0 °C at 760 mmHg | |
| Molecular Formula | C29H31F3N6O3 | Melting Point | N/A | |
| MSDS | USA | Flash Point | 403.8±32.9 °C | |
Use of WS6WS6 is a novel small molecule that promotes β cell proliferation in rodent and human primary islets with EC50 of 0.28 uM(R7T1 cell viability).EC50 value: 0.28 uM [1]Target: β cell proliferation agonistin vitro: WS6 induced up to 4% of rat β cells to proliferate, with an EC50 of 0.4 μM. In the same format, WS6 also induced 3% of human β cells to proliferate, with a similar potency to the rat β cells. WS6 induced R7T1 proliferation in dose response, with EC50 value of 0.28 μM, Proliferation of R7T1 cells, which are cultured in suspension and grow as clusters, was apparent by visible inspection. in vivo: RIP-DTA mice were fed Dox in the drinking water until the onset of overt diabetes (blood glucose reading >300 mg/dL, typically 4-10 days), at which point Dox treatment was discontinued and treatment with WS6 was initiated (5 mg/kg every other day via intraperitoneal injection). Pharmacokinetic studies with WS6 at 50 mg/kg revealed a CMAX of ～5 μM and T1/2 of ～2 h. Treatment with WS6 caused a progressive reduction of blood glucose over time, starting around 2 weeks. |
| Name | Benzeneacetamide, 4-[[6-[(cyclopropylcarbonyl)amino]-4-pyrimidinyl]oxy]-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]- |
|---|---|
| Synonym | More Synonyms |
| Description | WS6 is a novel small molecule that promotes β cell proliferation in rodent and human primary islets with EC50 of 0.28 uM(R7T1 cell viability).EC50 value: 0.28 uM [1]Target: β cell proliferation agonistin vitro: WS6 induced up to 4% of rat β cells to proliferate, with an EC50 of 0.4 μM. In the same format, WS6 also induced 3% of human β cells to proliferate, with a similar potency to the rat β cells. WS6 induced R7T1 proliferation in dose response, with EC50 value of 0.28 μM, Proliferation of R7T1 cells, which are cultured in suspension and grow as clusters, was apparent by visible inspection. in vivo: RIP-DTA mice were fed Dox in the drinking water until the onset of overt diabetes (blood glucose reading >300 mg/dL, typically 4-10 days), at which point Dox treatment was discontinued and treatment with WS6 was initiated (5 mg/kg every other day via intraperitoneal injection). Pharmacokinetic studies with WS6 at 50 mg/kg revealed a CMAX of ～5 μM and T1/2 of ～2 h. Treatment with WS6 caused a progressive reduction of blood glucose over time, starting around 2 weeks. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 744.1±60.0 °C at 760 mmHg |
| Molecular Formula | C29H31F3N6O3 |
| Molecular Weight | 568.590 |
| Flash Point | 403.8±32.9 °C |
| Exact Mass | 568.240967 |
| PSA | 99.69000 |
| LogP | 3.86 |
| Appearance of Characters | powder,white to beige |
| Vapour Pressure | 0.0±2.5 mmHg at 25°C |
| Index of Refraction | 1.630 |
| Storage condition | 2-8°C |
| Water Solubility | Insuluble (4.1E-3 g/L) (25 ºC) |
| RIDADR | NONH for all modes of transport |
|---|---|
| WGK Germany | 3 |
| Benzeneacetamide, 4-[[6-[(cyclopropylcarbonyl)amino]-4-pyrimidinyl]oxy]-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]- |
| N-(6-{4-[2-({4-[(4-Methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl}amino)-2-oxoethyl]phenoxy}-4-pyrimidinyl)cyclopropanecarboxamide |
| WS6 |
| 4-[[6-[(Cyclopropylcarbonyl)amino]-4-pyrimidinyl]oxy]-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzeneacetamide |